Brown Advisors, an investment management company, released its “Brown Advisors Global Leaders Strategy” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. In the letter the firm discusses its performance, four new investments made in 2024, lessons from one exit, and insights from its annual offsite. The strategy targets double-digit annualized returns over five years, aiming for 10%+ to double investors’ money every seven years. In 2024, the UCITS C-share USD returned 14.7% net of fees, while the MSCI ACWI benchmark returned 17.5%. Since inception, the Global Leaders UCITS C-share USD has delivered an annualized 11.4% net after fees, surpassing firm’s target, compared to the MSCI ACWI’s 8.9%. In addition, please check the fund’s top five holdings to know its best picks in 2024.
In its fourth quarter 2024 investor letter, Brown Advisors Global Leaders Strategy emphasized stocks such as Zoetis Inc. (NYSE:ZTS). Zoetis Inc. (NYSE: ZTS) is involved in the research, development, manufacturing, and sale of animal health medications, vaccines, and diagnostic products and services. The one-month return of Zoetis Inc. (NYSE:ZTS) was -3.46%, and its shares lost 13.54% of their value over the last 52 weeks. On February 27, 2025, Zoetis Inc. (NYSE:ZTS) stock closed at $164.98 per share with a market capitalization of $73.877 billion.
Brown Advisors Global Leaders Strategy stated the following regarding Zoetis Inc. (NYSE:ZTS) in its Q4 2024 investor letter:
“Zoetis Inc. (NYSE:ZTS) is the global leader in animal health serving both companion animals and livestock through medicines, vaccines, and diagnostics products. Zoetis spun out of U.S. pharma company Pfizer in 2013, having operated as it’s animal health division since 1952. It is the largest pure-play animal health company with significant scale in R&D, leading to innovation in drug discovery, which has allowed it to take market share from smaller competitors. It spends more per year on R&D than the next three players combined. Animal health is in many aspects more attractive than the wider pharma industry given the smaller number of competitors, lighter regulation for drug development (no human trials required) and less threat from generics. Zoetis has established itself as the highest quality marketer to the veterinarians and livestock producers, where quality and reliability of a drug are key competitive advantages, increasing switching costs, as it solves problems for vets and pet owners alike.”
A veterinarian administering a vaccine to a herd of cattle in a farm.
Zoetis Inc. (NYSE:ZTS) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 76 hedge fund portfolios held Zoetis Inc. (NYSE:ZTS) at the end of the fourth quarter compared to 62 in the third quarter. Zoetis Inc. (NYSE:ZTS) reported revenue of $9.3 billion for the year, reflecting an 8% increase on a reported basis and an 11% increase operationally. While we acknowledge the potential of Zoetis Inc. (NYSE:ZTS) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
In another article, we discussed Zoetis Inc. (NYSE:ZTS) and shared the list of best drug stocks to buy. In addition, please check out our hedge fund investor letters Q4 2024 page for more investor letters from hedge funds and other leading investors.
READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks.
Disclosure: None. This article is originally published at Insider Monkey.